Although the prevalence of EGFR-mutations is reported to vary in different studies and populations, we expect the proportion of unknown EGFRm+ patients to be low, as the proportions given in Table 1 is in line with the proportion of EGFRm+ NSCLC patients in comparable, European populations (19, 20). Here, EGFR is linked to non-small cell lung carcinoma.